Has APOL1 kidney disease treatment been hiding in plain sight?
Kidney International · 2024
DOI: 10.1016/j.kint.2024.09.003 ↗Kurz gefasst
Kommentar in der Zeitschrift Kidney International, 2024. Verfasst von Opeyemi A Olabisi. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, U…. Hauptthemen laut MEDLINE: Apolipoprotein L1, Glomerulosclerosis, Focal Segmental, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1-induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: Opeyemi.olabisi@duke.edu.
Zitieren
APA
Olabisi, O. A. (2024). Has APOL1 kidney disease treatment been hiding in plain sight?. Kidney International. https://doi.org/10.1016/j.kint.2024.09.003
Vancouver
Olabisi OA. Has APOL1 kidney disease treatment been hiding in plain sight?. Kidney International. 2024. doi:10.1016/j.kint.2024.09.003
BibTeX
@article{Olabisi2024,
author = {Olabisi, Opeyemi A},
title = {Has APOL1 kidney disease treatment been hiding in plain sight?},
journal = {Kidney International},
year = {2024},
doi = {10.1016/j.kint.2024.09.003}
}
EUVIMED